Institution
British Hospital
Healthcare•Montevideo, Uruguay•
About: British Hospital is a healthcare organization based out in Montevideo, Uruguay. It is known for research contribution in the topics: Population & Lung cancer. The organization has 445 authors who have published 358 publications receiving 7878 citations. The organization is also known as: British Hospital.
Papers published on a yearly basis
Papers
More filters
••
TL;DR: This paper offers a report of the behaviour of the blood pressure during the course of 4 pregnancies occurring in 2 women with coarctation of the aorta, comparing the readings with similar ones occurring in pregnant women suffering from essential hypertension.
8 citations
••
Central Institution for Meteorology and Geodynamics1, University of Queensland2, Fiona Stanley Hospital3, University of Western Australia4, University of Huddersfield5, Queensland University of Technology6, Royal Brisbane and Women's Hospital7, University of Paris8, British Hospital9, John Hunter Hospital10, Royal North Shore Hospital11, Nepean Hospital12, Royal Prince Alfred Hospital13, St George's Hospital14, Boston Children's Hospital15, Sydney Adventist Hospital16, Logan Hospital17, Toowoomba Hospital18, Lyell McEwin Hospital19, Calvary Wakefield Hospital20, Geelong Hospital21, Royal Melbourne Hospital22, Canberra Hospital23, St John of God Murdoch Hospital24, Royal Perth Hospital25, Wellington Hospital26
TL;DR: It is reported that ICU staff perceived open visiting as beneficial for relatives, but also identified risks to themselves, including increased workload, a risk of burnout, and the risk of occupational violence.
8 citations
••
Mayo Clinic1, University of Paris2, Cardiff University3, University of Leeds4, University of California, San Francisco5, Katholieke Universiteit Leuven6, Utrecht University7, University of Pisa8, University of Hamburg9, Hospital Clínico San Carlos10, University College London11, Ludwig Maximilian University of Munich12, Monash University13, British Hospital14, University of Southern California15
TL;DR: In this article, the authors investigated the impact of primary tumor sidedness (PTS) on outcomes of metastatic colorectal cancer patients and found that left-sidedness was associated with better prognosis among KRAS wild-type (WT) (OS HRadj = 0.59, 95% CI = 0.53-0.76, P<.001) and PFS (median = 8.6 v 7.5
Abstract: Background
Unplanned subgroup analyses from several studies have suggested primary tumor sidedness (PTS) as a potential prognostic and predictive parameter in metastatic colorectal cancer (mCRC). We aimed to investigate the impact of PTS on outcomes of mCRC patients.
Methods
PTS data of 9,277 mCRC patients from 12 first-line randomized trials in the ARCAD database were pooled. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier and Cox models adjusting for age, sex, performance status, prior radiation/chemo, and stratified by treatment arm. Predictive value was tested by interaction term between PTS and treatment (cetuximab plus chemotherapy vs. chemotherapy alone). All statistical tests were 2-sided.
Results
Compared to right-sided metastatic colorectal cancer patients (n = 2421, 26.1%), left-sided metastatic colorectal cancer patients (n = 6856, 73.9%) had better OS (median = 21.6 v 15.9 months; adjusted hazard ratio [HRadj] = 0.71, 95% confidence interval [CI] = 0.67–0.76, P<.001) and PFS (median = 8.6 v 7.5 months; HRadj = 0.80, 95% CI = 0.75–0.84, P<.001). Interaction between PTS and KRAS mutation was statistically significant (Pinteraction<.001): left-sidedness was associated with better prognosis among KRAS wild-type (WT) (OS HRadj = 0.59, 95% CI = 0.53–0.66; PFS HRadj =0.68, 95% CI = 0.61–0.75), but not among KRAS mutated tumors. Among KRAS-WT tumors, survival benefit from anti-EGFR was confirmed for left-sidedness (OS HRadj = 0.85, 95% CI = 0.75–0.97, P = .01; PFS HRadj = 0.77, 95% CI = 0.67–0.88, P<.001), but not for right-sidedness.
Conclusions
The prognostic value of PTS is restricted to the KRAS-WT population. PTS is predictive of anti-EGFR efficacy, with a statistically significant improvement of survival for left-sidedness mCRC patients. These results suggest treatment choice in mCRC should be based on both PTS and KRAS status.
8 citations
••
TL;DR: The data suggest that in patients with PTFEG the 4G/5G variant might be associated with an increased thrombosis risk, and PAI-1 levels were elevated in HD patients, independent of their polymorphic variants.
Abstract: Introduction: Chronic insufficiency alters homeostasis, in part due to endothelial inflammation. Plasmi- nogen activator inhibitor-1 (PAI-1) is increased in renal disease, contributing to vascular damage. We assessed PAI- 1 activity and PAI-1 4G/5G polymorphism in hemodialysis (HD) subjects and any association between thrombotic vascular access (VA) events and PAI-1 polymorphism. Methods: Prospective, observational study in 36 HD patients: mean age: 66.6 ± 12.5 yr, males n=26 (72%), time on HD: 28.71 ± 22.45 months. Vascular accesses: 10 polytetrafluoroethylene grafts (PTFEG), 22 arteriovenous fistu- lae (AVF), four dual lumen catheters (CAT). Control group (CG): 40 subjects; mean age: 60.0 ± 15 yrs, males n=30 (75%). Group A (GA): thrombotic events (n=12), and group B (GB): No events (n=24). Groups were no different according to age (69.2 ± 9.12 vs. 65.3 ± 14.5 yrs), gender (males: 7; 58.3% vs. 18; 81.8%), time on HD (26.1 ± 14.7 vs. 30.1 ± 38.7 months), causes of renal failure. Time to follow-up for access thrombosis: 12 months. Results: PAI-1 levels in HD: 7.21 ± 2.13 vs. CG: 0.42 ± 0.27 U/ml (p<0.0001). PAI-1 4G/5G polymorphic variant di- stribution in HD: 5G/5G: 6 (17%), 4G/5G: 23 (64%); 4G/4G: 7 (19%) and in CG: 5G/5G: 14 (35%); 4G/5G: 18 (45%); 4G/4G: 8 (20%). C-reactive protein (CRP) in HD: 24.5 ± 15.2 mg/L vs. in CG 2.3 ± 0.2 mg/L (p<0.0001). PAI-1 4G/5G variants: GA: 5G/5G: 3; 4G/5G: 8; 4G/4G: 1; GB: 5G/5G: 3; 4G/5G: 15; 4G/4G: 6. Thrombosis occurred in 8/10 patients (80%) with PTFEG, 3/22 (9%) in AVF, and 1/4 (25%) in CAT. Among the eight PTFEG patients with thrombosis, seven were PAI 4G/5G. Conclusions: PAI-1 levels were elevated in HD patients, independent of their polymorphic variants, 4G/5G being the most prevalent variant. Our data suggest that in patients with PTFEG the 4G/5G variant might be associated with an increased thrombosis risk. (J Vasc Access 2008; 9: 142-7)
8 citations
••
TL;DR: It is the understanding that the smoking habit should be considered as a common etiology for mild leucocytosis and neutrophilia in smokers with no other pulmonary associated disease.
8 citations
Authors
Showing all 445 results
Name | H-index | Papers | Citations |
---|---|---|---|
Maité Garrouste-Orgeas | 62 | 157 | 13270 |
A. de Gramont | 41 | 178 | 11918 |
Ricardo F. Allegri | 33 | 220 | 3577 |
Benoist Chibaudel | 32 | 141 | 4272 |
Emmanuel Marret | 29 | 98 | 4779 |
Federico G. Villamil | 26 | 82 | 3829 |
Oscar E. Martínez | 25 | 174 | 4785 |
Daniel Moya | 21 | 82 | 1236 |
João Guimarães | 19 | 30 | 2206 |
Silvia Quadrelli | 18 | 110 | 1095 |
Jose C. Russi | 17 | 25 | 761 |
Alvaro Campero | 17 | 94 | 1230 |
Hernán Trimarchi | 17 | 79 | 1207 |
Matias Bruzoni | 16 | 46 | 845 |
Hamlet Suarez | 16 | 41 | 914 |